Your browser doesn't support javascript.
loading
Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome.
Parmentier, Cyrielle; Delbet, Jean-Daniel; Decramer, Stéphane; Boyer, Olivia; Hogan, Julien; Ulinski, Tim.
Afiliação
  • Parmentier C; Pediatric Nephrology Unit, Armand Trousseau Hospital, APHP.6, 75012, Paris, France.
  • Delbet JD; Sorbonne University, Paris, France.
  • Decramer S; Inflammation-Immunopathology-Biotherapy, DHU i2b, Paris, France.
  • Boyer O; Pediatric Nephrology Unit, Armand Trousseau Hospital, APHP.6, 75012, Paris, France.
  • Hogan J; Inflammation-Immunopathology-Biotherapy, DHU i2b, Paris, France.
  • Ulinski T; Pediatric Nephrology and Rheumatology, CHU, Toulouse, France.
Pediatr Nephrol ; 35(3): 455-462, 2020 03.
Article em En | MEDLINE | ID: mdl-31705306
ABSTRACT

BACKGROUND:

Rituximab (RTX) is efficient in steroid-dependent nephrotic syndrome (SDNS) in pediatric and adult patients. The aim of this study is to describe hypogammaglobulinemia as a side effect of RTX treatment.

METHODS:

All pediatric patients (< 18 years old) of four French pediatric nephrology centers who received RTX for SDNS between 2010 and 2015 have been included. Clinical and biological data have been analyzed retrospectively before, during, and after RTX treatment. Hypogammaglobulinemia was defined as an IgG level < - 2 standard deviations for patient age.

RESULTS:

A total of 107 pediatric patients have been included, 65.9% were boys, median age at nephrotic syndrome diagnosis was 3.1 interquartile range [IQ 2.24-5.45] years and age at RTX introduction was 11.7 [IQ 8.6-14.2] years. Twenty-one patients had hypogammaglobulinemia before the initiation of RTX. Of the patients, 25/86 had at least one hypogammaglobulinemia during B cell depletion or after B cell recovery while IgG levels at initiation were normal with a persisting hypogammaglobulinemia for 13 patients 1 year after B cell recovery. Patients who developed hypogammaglobulinemia were younger at RTX initiation with a median age of 8.2 years [IQ 6.3-12.4]. Among all the 46 patients with hypogammaglobulinemia during follow-up, 13 had a concomitant infection.

CONCLUSIONS:

Hypogammaglobulinemia is a frequent complication of RTX treatment in younger children treated for SDNS. The use of RTX in children has to be carefully evaluated and their clinical and biological follow-up should be adapted to the age-dependent risk profile for hypogammaglobulinemia.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Agamaglobulinemia / Rituximab / Imunossupressores / Síndrome Nefrótica Tipo de estudo: Diagnostic_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Agamaglobulinemia / Rituximab / Imunossupressores / Síndrome Nefrótica Tipo de estudo: Diagnostic_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article